Active Ingredient History
Midodrine is a prodrug, i.e., the therapeutic effect of orally administered midodrine is due to the major metabolite desglymidodrine formed by deglycination of midodrine. Desglymidodrine diffuses poorly across the blood-brain barrier, and is therefore not associated with effects on the central nervous system. Administration of midodrine results in a rise in standing, sitting, and supine systolic and diastolic blood pressure in patients with orthostatic hypotension of various etiologies. Standing systolic blood pressure is elevated by approximately 15 to 30 mmHg at 1 hour after a 10-mg dose of midodrine, with some effect persisting for 2 to 3 hours. Midodrine has no clinically significant effect on standing or supine pulse rates in patients with autonomic failure. Midodrine forms an active metabolite, desglymidodrine, that is an alpha1-agonist, and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac beta-adrenergic receptors. Midodrine is used for the treatment of symptomatic orthostatic hypotension (OH). Midodrine is marketed under the brand names Amatine, ProAmatine, Gutron. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypotension, Orthostatic (approved 2004)
Acute Kidney Injury (Early Phase 1)
Ascites (Phase 4)
Autonomic Dysreflexia (Phase 2)
Autonomic Nervous System Diseases (Phase 2)
Baroreflex (Phase 2)
Blood Pressure (Phase 2)
Cardiopulmonary Bypass (Phase 4)
Cerebrovascular Circulation (Phase 2)
Cognition (Phase 2)
Cognitive Dysfunction (Phase 4)
Critical Illness (Phase 4)
Fibrosis (Phase 4)
Healthy Volunteers (Phase 1)
Hepatic Encephalopathy (Phase 4)
Hepatorenal Syndrome (Phase 2/Phase 3)
Hyponatremia (Phase 4)
Hypotension (Phase 4)
Hypotension, Orthostatic (Phase 4)
Hypothermia (Phase 4)
Infections (Phase 4)
Influenza A virus (Phase 2)
Intestinal Neoplasms (Phase 4)
Ischemic Stroke (Phase 2)
Lung Diseases (Phase 1)
Multiple System Atrophy (Phase 1/Phase 2)
Orthostatic Intolerance (Phase 1/Phase 2)
Paracentesis (Phase 3)
Parkinson Disease (Phase 1)
Postoperative Complications (Phase 3)
Pure Autonomic Failure (Phase 1/Phase 2)
Quadriplegia (Phase 4)
Renal Insufficiency (Phase 4)
Sepsis (Phase 4)
Shock (Phase 4)
Shock, Septic (Phase 4)
Spinal Cord Injuries (Phase 3)
Syncope, Vasovagal (Phase 4)
Tachycardia (Phase 1/Phase 2)
Vagus Nerve (Phase 2)
Vasoplegia (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
